The U.S. FDA has approved belzutifan for use in adults and pediatric patients with certain types of tumors. Belzutifan demonstrated efficacy in reducing tumor size and antihypertensive medication use. Common adverse reactions include anemia, fatigue, musculoskeletal pain, and others. Clinicians should report serious adverse events to the FDA MedWatch system.

Source: FDA